Deng Hong, Lv Ye, Fu Jie
Department of Infectious Diseases, the Second Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Zhonghua Gan Zang Bing Za Zhi. 2004 Jun;12(6):368-9.
To investigate the relationship between curative effect and incidence rate of the YMDD mutations of hepatitis B virus during lamivudine treatment for chronic hepatitis B patients twenty-four weeks.
120 patients with chronic hepatitis B were treated with lamivudine (100 mg/d) over 24 weeks. The levels of serum ALT and HBV-DNA and clinical symptoms were detected at baseline and the 24th weeks after treatment. HBV-DNA YMDD mutation in 17 patients was detected by gene chips at baseline and the 24th weeks.
(1) Beside I case of YMDD/YVDD mutation was found before lamivudine treatment, 7 mutation were found after 24 weeks treatment, 2 with pure mutation strain, one of them was YIDD mutation, and the other was YVDD mutation; 2 and 3 others were YVDD/YMDD mutations and YMDD/YVDD mutations respectively. (2) The serum ALT and HBV DNA levels of YMDD mutation group showed no significantly change compared with normal group at baseline and 24th week.
The level of serum ALT and HBV DNA showed no significantly changes with the incidence of YMDD mutations at the 24 week treatment
探讨慢性乙型肝炎患者拉米夫定治疗24周时疗效与乙型肝炎病毒YMDD突变发生率之间的关系。
120例慢性乙型肝炎患者接受拉米夫定(100mg/d)治疗24周。在基线及治疗后第24周检测血清ALT、HBV-DNA水平及临床症状。对17例患者在基线及第24周时用基因芯片检测HBV-DNA YMDD突变。
(1)拉米夫定治疗前发现1例YMDD/YVDD突变,治疗24周后发现7例突变,其中2例为单纯突变株,1例为YIDD突变,另1例为YVDD突变;另2例和3例分别为YVDD/YMDD突变和YMDD/YVDD突变。(2)YMDD突变组血清ALT和HBV DNA水平在基线及第24周时与正常组相比无明显变化。
治疗24周时,血清ALT和HBV DNA水平与YMDD突变发生率无明显变化